Solara Active Pharma Sciences Ltd
SOLARA (NSE)

342.85

1,234.13
Proj. ROE (%)
3.90
Proj. P/E (x)
21.84
Proj EV / EBITDA (x)
6.02
Proj. P/BV (x)
0.80
Proj. Revenue ( Cr.)
1,548.12

Stock View

BUY
Share on
The average score for Solara Active Pharma Sciences Ltd stands at 3 against 3, three months back.

Solara Active Pharma Sciences Limited is an India-based company, which is engaged in the business of manufacturing and development of active pharmaceutical ingredients (API). The Company is involved in contract manufacturing and development services for global companies. Its commercial products include Aprepitant (Antiemetic), Brivaracetam (Antiepileptic), Bumetanide (Inj) (Loop Diuretic), Buspirone Hcl (Anxiolytic), Cevimeline Hydrochloride (Muscarinic Agonist), Cinacalcet Hydrochloride (Calcimimetic Agent), Citicoline Sodium (Anticonvulsant), Colchicine (Antigout Agent), Disulfiram (Chronic Alcoholism), Edaravone (Recovery Of Stroke), Etomidate (Anesthetics), Felbamate (Anticonvulsant), Flecainide Acetate (Anti-Arrhythmic Agent), Rifaximin (Antibiotic), S-Ibuprofen (Anti-Inflammatory), Oseltamivir Phosphate(Antiviral) and Levetiracetam (Anticonvulsant). It provides services, such as synthetic development, analytical development, process engineering, and regulatory services.

Disclaimer : All estimates (1 year forward) are based on Consensus View provided by Refinitiv.

Technical Data
50 DMA()
426.71
100 DMA ()
571.34
200 DMA ()
892.25
52 Weeks Range
320.00
1,827.00
Street View :-
Bearish
Open ZERO Brokerage Demat Account
Open Demat Account

  • 0

    Per Order for ETF & Mutual Funds Brokerage

  • 20

    Per Order for Delivery, Intraday, F&O, Currency & Commodity